CAPR - Capricor Therapeutics stock rises Oppenheimer initiates coverage at Outperform
2024-05-17 10:09:23 ET
Capricor Therapeutics ( NASDAQ: CAPR ) has been initiated at Outperform by Oppenheimer on hopes of positive outcome from the company’s Phase 3 trial of its Duchenne muscular dystrophy treatment....
Capricor Therapeutics stock rises, Oppenheimer initiates coverage at Outperform